Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven…
| Métrica | ANL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -203.5% | -39.2% | -164.4% |
| ROA | -72.8% | -30.9% | -41.8% |
| Current Ratio | 1.41 | 2.73 | -1.32 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -72.8% | — |
| ✗Flujo de caja operativo positivo | −$52M | −$57M |
| ✓Rentabilidad sobre activos al alza | -72.8% | -83.9% |
| ✓Caja operativa/activos supera al ROA | -72.7% | ROA -72.8% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.41 | 2.04 |
| ✗Sin aumentar el nº de acciones | 96M | 43M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | — | 0.04 |
| Calidad del negocio | FY24 |
|---|---|
| ✗ROCE > 10 % | -204.3% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
Adlai Nortye Group Ltd. cotiza a 11.03 USD y tiene una capitalización bursátil de $710M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud